ATE432695T1 - Neue verwendung einer polyamin-armen zusammensetzung zur herstellung eines medizinischen nahrungsmittels für den menschlichen verzehr - Google Patents

Neue verwendung einer polyamin-armen zusammensetzung zur herstellung eines medizinischen nahrungsmittels für den menschlichen verzehr

Info

Publication number
ATE432695T1
ATE432695T1 AT04767761T AT04767761T ATE432695T1 AT E432695 T1 ATE432695 T1 AT E432695T1 AT 04767761 T AT04767761 T AT 04767761T AT 04767761 T AT04767761 T AT 04767761T AT E432695 T1 ATE432695 T1 AT E432695T1
Authority
AT
Austria
Prior art keywords
pain
diet
low
group
demonstrating
Prior art date
Application number
AT04767761T
Other languages
English (en)
Inventor
Jacques-Philippe Moulinoux
Guy Simonnet
Original Assignee
Univ Rennes
Univ Victor Segalen Bordeaux I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rennes, Univ Victor Segalen Bordeaux I filed Critical Univ Rennes
Application granted granted Critical
Publication of ATE432695T1 publication Critical patent/ATE432695T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
AT04767761T 2003-07-31 2004-07-22 Neue verwendung einer polyamin-armen zusammensetzung zur herstellung eines medizinischen nahrungsmittels für den menschlichen verzehr ATE432695T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309480A FR2858231B1 (fr) 2003-07-31 2003-07-31 Utilisation nouvelle d'une composition alimentaire a usage humain pauvre en polyamines pour la realisation d'un aliment therapeutique
PCT/FR2004/001962 WO2005020974A1 (fr) 2003-07-31 2004-07-22 Utilisation nouvelle d’une composition pauvre en polyamines pour la realisation d’un aliment therapeutique humain

Publications (1)

Publication Number Publication Date
ATE432695T1 true ATE432695T1 (de) 2009-06-15

Family

ID=34043717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04767761T ATE432695T1 (de) 2003-07-31 2004-07-22 Neue verwendung einer polyamin-armen zusammensetzung zur herstellung eines medizinischen nahrungsmittels für den menschlichen verzehr

Country Status (11)

Country Link
US (1) US9023417B2 (de)
EP (1) EP1648431B1 (de)
JP (2) JP2007500687A (de)
AT (1) ATE432695T1 (de)
CA (1) CA2533690C (de)
DE (1) DE602004021382D1 (de)
DK (1) DK1648431T3 (de)
ES (1) ES2331613T3 (de)
FR (1) FR2858231B1 (de)
HK (1) HK1092696A1 (de)
WO (1) WO2005020974A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896127B1 (fr) 2006-01-17 2008-04-11 Univ Rennes I Etablissement Pu Utilisation nouvelle d'une composition alimentaire a usage humain ou veterinaire pauvre en polyamines pour la realisation d'un aliment therapeutique
FR2967868B1 (fr) * 2010-11-30 2012-11-09 Univ Dauvergne Clermont I Utilisation d'une composition alimentaire dans le traitement et/ou la prevention des douleurs neuropathiques induites par un agent anticancereux
FR2979241B1 (fr) 2011-08-30 2014-05-09 Nutrialys Medical Nutrition Sa Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux
FR2980709B1 (fr) * 2011-09-29 2013-10-25 Nutrialys Medical Nutrition Sa Compositions contenant de la spermine et compositions pharmaceutiques les contenant
FR2985427B1 (fr) * 2012-01-10 2016-07-15 Nutrialys Medical Nutrition Sa Compositions contenant de l'agmatine et leurs utilisations dans la preparation de medicaments ou de substances nutraceutiques
EA028069B1 (ru) * 2014-05-30 2017-10-31 Общество с ограниченной ответственностью "Лактокор" Пептид, обладающий ноотропным действием, композиции на его основе и способы их применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706254B1 (fr) * 1993-06-17 1995-08-25 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines.
FR2706255B1 (fr) * 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2318004A1 (en) * 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
FR2858231B1 (fr) 2006-02-10
CA2533690A1 (en) 2005-03-10
US20070184151A1 (en) 2007-08-09
US9023417B2 (en) 2015-05-05
HK1092696A1 (en) 2007-02-16
ES2331613T3 (es) 2010-01-11
CA2533690C (en) 2013-06-11
FR2858231A1 (fr) 2005-02-04
EP1648431A1 (de) 2006-04-26
JP2007500687A (ja) 2007-01-18
JP5501395B2 (ja) 2014-05-21
EP1648431B1 (de) 2009-06-03
JP2012144540A (ja) 2012-08-02
DK1648431T3 (da) 2009-09-14
DE602004021382D1 (de) 2009-07-16
WO2005020974A1 (fr) 2005-03-10

Similar Documents

Publication Publication Date Title
Henter et al. Novel glutamatergic modulators for the treatment of mood disorders: current status
Anton et al. Flipping the metabolic switch: understanding and applying the health benefits of fasting
Frampton et al. Pregabalin: in the treatment of painful diabetic peripheral neuropathy
Mairesse et al. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats
Chiang et al. Astroglial glutamate–glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn
Fairbanks et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury
Wood The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo?
HK1092696A1 (en) Novel use of a polyamine-poor composition for the production of a medical human food
Perucca et al. Lacosamide
JP5902148B2 (ja) 自閉症治療用ジメチルスルホキシド（ｄｍｓｏ）製剤
AU2005200619A1 (en) Method for the treatment of incontinence
Dézsi et al. Safinamide for the treatment of Parkinson's disease
Nilsson et al. Glycine and D-serine decrease MK-801-induced hyperactivity in mice
US20220387373A1 (en) Neurodevelopmental disorder therapy
Spann et al. Effect of clenbuterol on athletic performance
Zarrindast et al. Role of nitric oxide in the acquisition and expression of apomorphine-or morphine-induced locomotor sensitization
Raziya Banu et al. Ameliorative effect of Withaferin A on ageing-mediated impairment in the dopamine system and its associated behavior of Wistar Albino Rat
Skolnick et al. Triple reuptake inhibitors (“broad spectrum” antidepressants)
Karolewicz et al. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: 2. Chronic treatment results in downregulation of cortical β-adrenoceptors
Zhand et al. Glutamate modulators for treatment of schizophrenia
Head et al. The effects of L-deprenyl on spatial short term memory in young and aged dogs
CL2007002324A1 (es) Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular.
Cui et al. Effects of noradrenergic and serotonergic systems on risk-based decision-making and center arena activity in open field in rats
Dai et al. Gender differences in the antinociceptive effect of tramadol, alone or in combination with gabapentin, in mice
Forst et al. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648431

Country of ref document: EP